Disclaimer: The information, documents and graphic depictions (the "Information") published on this Web site are the property of LIfT BioSciences Ltd. LIfT BioSciences assumes no responsibility for errors or omissions in the Information on this website. In no event shall LIfT BioSciences be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. LIfT BioSciences reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.

  • CEO's Linked-in
  • CEO's Twitter
  • LIfTBio on Facebook

©2016 LIfT BioSciences Ltd


Innately Curing Cancer

LIfT BioSciences is a socially-minded Biotech start-up developing The World's First Cell Bank of Cancer Killing Neutrophils (a type of white blood cell) to destroy all solid tumours, irrespective of strain or mutation.  The Cell Bank will enable us to provide a range of potentially life-saving immuno-oncology cell therapies for different solid tumour types. Our innate immunity platform is known as Neutrophil only Leukocyte Infusion Therapy (N-LIfT), a first-in-class patented cell therapy. N-LIfT is produced ex-vivo and benefits from being more scalable with potentially better and more consistent efficacy and safety than other forms of leukocyte infusion.

LIfT BioSciences Ltd was set-up with Prof Zhen Cui of Wake Forest University, a leading pioneer in LIFT, following his discovery of a cancer resistant (SR/CR) mouse that proved to have transferable innate immunity. 

The first targeted indication is pancreatic cancer (pancreatic ductal adenocarcinoma – PDAC), one of the types of cancer with the highest unmet medical need. CRUK report that just 3% of Patients Diagnosed with PDAC survive 5 years. PDAC is classified as an orphan disease by European Medicines Agency (EMA) which will facilitate our market access. The EMA has classified N-LIfT as an Advanced Therapeutic Medicinal Product (ATMP), which sets us up for  accelerated approval (early access scheme) and enhanced proprietary protection (market and data exclusivity), subject to trial results.

We are currently completing pre-clinical work before running our first in-human clinical trial. The aim is to demonstrate remission in high unmet need solid tumours by 2021, including Pancreatic Cancer.  

Due to the sensitivity of our work and the IP required to successfully bring this therapy to market we are unable to disclose more at present. If you would like to find out more, or if you would be interested in investing please Contact Us

The video below shows LIfT in action killing Cervical Cancer Cells: